|
NO811118L
(no)
|
1980-04-03 |
1981-10-05 |
Biogen Nv |
Dna-sekvenser, rekombinante dna-molekyler og fremgangsmaate ved fremstilling av polypeptider
|
|
WO1986000639A1
(en)
*
|
1984-07-06 |
1986-01-30 |
Sandoz Ag |
Lymphokine production and purification
|
|
JPS61227526A
(ja)
*
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
UA29377C2
(uk)
*
|
1984-09-19 |
2000-11-15 |
Новартіс Аг |
Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
|
|
NZ214225A
(en)
*
|
1984-11-20 |
1991-05-28 |
Schering Biotech Corp |
Polypeptides exhibiting human granulocyte/macrophage colony stimulating factor activity and their production
|
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
|
EP0220520B1
(en)
*
|
1985-09-30 |
1991-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Human granulocyte colony stimulating factor
|
|
JPH0618778B2
(ja)
*
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
|
DE3545568A1
(de)
*
|
1985-12-21 |
1987-07-16 |
Hoechst Ag |
Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
|
|
US5298603A
(en)
*
|
1985-12-21 |
1994-03-29 |
Hoechst Aktiengesellschaft |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
|
|
EP0232707A1
(en)
*
|
1986-01-09 |
1987-08-19 |
Ajinomoto Co., Inc. |
Human hematopoietic cell growth potentiating factor
|
|
US5106733A
(en)
*
|
1987-06-25 |
1992-04-21 |
Immunex Corporation |
Bovine granulocyte-macrophage colony stimulating factor
|
|
AU615550B2
(en)
*
|
1988-04-21 |
1991-10-03 |
Medvet Science Pty. Ltd. |
Human gm-csf variants
|
|
AU637133B2
(en)
*
|
1989-08-11 |
1993-05-20 |
Amrad Operations Pty. Limited |
Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
|
|
ATE215989T1
(de)
|
1993-09-15 |
2002-04-15 |
Chiron Corp |
Rekombinanter alphavirus vektor
|
|
WO1995023862A1
(en)
*
|
1994-03-04 |
1995-09-08 |
Ludwig Institute For Cancer Research |
Animals with targeted gene disruption
|
|
JP4383530B2
(ja)
|
1996-04-05 |
2009-12-16 |
ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド |
細胞巨大分子合成の阻害が減少したアルファウイルスベクター
|
|
WO1998012332A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
CN1269805A
(zh)
*
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
ATE257392T1
(de)
|
1997-10-02 |
2004-01-15 |
Max Planck Gesellschaft |
Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
JP2002533124A
(ja)
|
1998-12-31 |
2002-10-08 |
カイロン コーポレイション |
Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
EP1150666B1
(en)
*
|
1999-02-12 |
2009-10-28 |
Washington University |
Gm-csf for the treatment of crohn's disease
|
|
US6911204B2
(en)
*
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
|
KR20030064377A
(ko)
*
|
2000-08-11 |
2003-07-31 |
파브릴, 인크. |
Ｔ 세포 매개 병증을 개선시키기 위한 방법 및 조성물
|
|
EP1409694A4
(en)
|
2001-07-05 |
2006-02-08 |
Chiron Corp |
POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US7381801B2
(en)
|
2002-02-13 |
2008-06-03 |
Ludwig Institute For Cancer Research |
Chimerized GM-CSF antibodies
|
|
AU2003228751A1
(en)
|
2002-05-01 |
2003-11-17 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
|
GB0210741D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Medical Res Council |
Methods of therapy
|
|
GB0224415D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Medical Res Council |
Compositions
|
|
AU2004269320B2
(en)
|
2003-06-20 |
2009-12-24 |
Protein Sciences Corporation |
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
|
|
EP1814583A2
(en)
|
2004-11-01 |
2007-08-08 |
Novartis Vaccines and Diagnostics, Inc. |
Combination approaches for generating immune responses
|
|
GB0524103D0
(en)
|
2005-11-26 |
2006-01-04 |
Medical Res Council |
Healing
|
|
KR101395515B1
(ko)
|
2006-02-08 |
2014-05-14 |
모르포테크, 인크. |
항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
|
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
|
EP2498795B1
(en)
|
2009-10-12 |
2016-12-07 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Granulysin in immunotherapy
|
|
US20140030218A1
(en)
|
2011-01-05 |
2014-01-30 |
Imperial Innovations Limited |
Treatment And Screening
|
|
WO2014008475A2
(en)
|
2012-07-05 |
2014-01-09 |
The Ohio State University |
Compositions and methods related to viral vaccines
|
|
WO2017040387A2
(en)
|
2015-08-31 |
2017-03-09 |
Technovax, Inc. |
Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
|
|
WO2017118865A1
(en)
|
2016-01-08 |
2017-07-13 |
Replimune Limited |
Oncolytic virus strain
|
|
WO2017180770A1
(en)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
|
WO2018075235A1
(en)
|
2016-10-17 |
2018-04-26 |
Synthetic Genomics, Inc. |
Recombinant virus replicon systems and uses thereof
|
|
MX2019006467A
(es)
|
2016-12-05 |
2019-12-09 |
Janssen Pharmaceuticals Inc Star |
Composiciones y métodos para mejorar la expresión génica.
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
|
BR112020014525A2
(pt)
|
2018-01-19 |
2020-12-08 |
Janssen Pharmaceuticals, Inc. |
Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
|